BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
GMAB upcoming catalysts
Genmab: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 7 readout(s) and 1 FDA event(s). Subscribe to GMAB (.ics).
Drugs: Pembrolizumab, Paclitaxel, Gemcitabine, Topotecan, Lenalidomide, Cisplatin, Carboplatin, Pemetrexed
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| No trials in this window. | ||||||
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-03-27 | FDA approval | approved | GENMAB US, INC. GMAB | EPKINLY | Approved 2026-03-27: EPKINLY (BLA761324 SUPPL10) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-08-18 | P3 | Genmab GMAB | NCT06619236 Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Platinum-resistant Ovarian Cancer | active not recruiting | 584 |
| 2026-06-10 | P2 | Genmab GMAB | NCT05660967 Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma | terminated | 111 |
| 2026-05-15 | P2 | Genmab GMAB | NCT06984328 Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With | Cutaneous Melanoma; Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, o | terminated | 1 |
| 2026-03-30 | P1/P2 | Genmab GMAB | NCT06685068 A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | terminated | 23 |
| 2026-03-25 | P1/P2 | Genmab GMAB | NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial | Breast Cancer, Breast Neoplasms; Endometrial Cancer, Endometrial Neoplasm; Ovarian Cancer, Ovarian N | terminated | 179 |
| 2025-12-30 | P1/P2 | Genmab GMAB | NCT04083599 GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | Malignant Solid Tumor; Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Melanoma; Head a | active not recruiting | 350 |
| 2025-11-20 | P1/P2 | Genmab GMAB | NCT06391775 Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy | Malignant Solid Tumor | terminated | 21 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.